Topical application of anthranilate derivatives ameliorates psoriatic inflammation in a mouse model by inhibiting keratinocyte‐derived chemokine expression and neutrophil infiltration
Open Access
- 19 June 2018
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 32 (12) , 6783-6795
Abstract
Psoriasis is an inflammatory autoimmune skin disorder possessing a complex etiology related to genetic and environmental triggers. Keratinocytes show a potential role for the origin of psoriasis. In this study, we estimated the efficiency of 2 anthranilate derivatives—( E )‐4‐( N ‐{2‐[1‐(hydroxyimino)ethyl]phenyl}sulfamoyl)phenyl pivalate (HFP031) and butyl 2‐[2‐(2‐fluorophenyl)acetamido]benzoate (HFP034)—on psoriasis amelioration in a mouse model. The results showed that topical treatment with both compounds could attenuate epidermal thickness and scaling in an imiquimod (IMQ)‐induced psoriasis mouse model via decreased expression of cytokines and chemokines [C‐X‐C chemokine ligand (CXCL)1 and CXCL2], leading to the reduction of neutrophilic abscess in the skin. The in vivo cutaneous absorption of HFP034 was 7.6‐fold greater than that of HFP031. Both compounds caused negligible irritation on healthy mouse skin. In addition, we examined the effect of the anthranilate derivatives on chemokine expression in IMQ‐treated HaCaT keratinocytes. Our results elucidated a mechanism for anti‐inflammatory activity of HFP034 that involved the elevation of intracellular cAMP concentration, suppression of NF‐κB activity, and attenuation of neutrophil chemoattractant expression. These results suggest that HFP034 could increase the cutaneous concentration of cAMP to suppress neutrophil infiltration into the skin. Topically applied HFP034 may demonstrate a potential for future clinical application as a novel therapy for psoriasis treatment.—Lin, Z.‐C., Hsieh, P.‐W., Hwang, T.‐L., Chen, C.‐Y., Sung, C. T., Fang, J.‐Y. Topical application of anthranilate derivatives ameliorates psoriatic inflammation in a mouse model by inhibiting keratinocyte‐derived chemokine expression and neutrophil infiltration. FASEB J. 32, 6783–6795 (2018). www.fasebj.orgKeywords
This publication has 48 references indexed in Scilit:
- The Chemokine Superfamily RevisitedImmunity, 2012
- Anthranilic acid-based inhibitors of phosphodiesterase: Design, synthesis, and bioactive evaluationOrganic & Biomolecular Chemistry, 2011
- In touch with psoriasis: topical treatments and current guidelinesJournal of the European Academy of Dermatology and Venereology, 2011
- Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseasesTherapeutic Advances in Musculoskeletal Disease, 2010
- Soluble Adenylyl Cyclase Defines a Nuclear cAMP Microdomain in Keratinocyte Hyperproliferative Skin DiseasesJournal of Investigative Dermatology, 2010
- The adenylyl cyclase-cAMP system suppresses TARC/CCL17 and MDC/CCL22 production through p38 MAPK and NF-κB in HaCaT keratinocytesMolecular Immunology, 2009
- Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 AxisThe Journal of Immunology, 2009
- Psoriasis: Improving adherence to topical therapyJournal of the American Academy of Dermatology, 2008
- Psoriasis: the epidermal componentClinics in Dermatology, 2007
- The Small Antitumoral Immune Response Modifier Imiquimod Interacts with Adenosine Receptor Signaling in a TLR7- and TLR8-Independent FashionJournal of Investigative Dermatology, 2006